Difference between revisions of "Team:Paris Bettencourt/Acceptance"
Line 24: | Line 24: | ||
<p><b>Contact person:</b> Dr. A. K. Sharma, on the behalf of the Chairperson and CEO of Food Safety and Standard Authority in India (FSSAI).</p> | <p><b>Contact person:</b> Dr. A. K. Sharma, on the behalf of the Chairperson and CEO of Food Safety and Standard Authority in India (FSSAI).</p> | ||
− | <b>Advice:</b> Choose the right microorganisms so they can survive and work | + | <b>Advice:</b> Choose the right microorganisms so they can survive and work together, along with the use of critical genes for the vitamin pathways. Concerning the law, he said that there is currently no authorisation for GMO microorganisms in the Indian Food regulation and if we want to have our product in India, its safety needs to be established. |
<p><b>Contact person:</b> Dr. Sunita Grover, principal scientist and head of the Dairy Microbiology Division at the National Dairy Research Institute</></p> | <p><b>Contact person:</b> Dr. Sunita Grover, principal scientist and head of the Dairy Microbiology Division at the National Dairy Research Institute</></p> | ||
− | <b>Advice:</b> Use food grade vector system to make sure our product is safe for consumption and to reduce issues arising | + | <b>Advice:</b> Use food grade vector system to make sure our product is safe for consumption and to reduce issues arising from the |
use of genetically modified bacteria. She had concerns about the compatibility of the different species | use of genetically modified bacteria. She had concerns about the compatibility of the different species | ||
living in fermentation batter. To finish, her major | living in fermentation batter. To finish, her major | ||
− | concern is safety. | + | concern is safety. Our project needs to undergo phase I and II trials in order to assess safety and scientifically proven health benefits. |
She was surprised and really enthusiastic towards the project because malnutrition is a serious problem in India and many children suffer from it | She was surprised and really enthusiastic towards the project because malnutrition is a serious problem in India and many children suffer from it | ||
our project. | our project. | ||
Line 38: | Line 38: | ||
<p><b>Contact person:</b> Prof. Samir K. Brahmachari, former director of India's main research body - The Council of Scientific and Industrial Research (CSIR); Chief mentor, Open Source Drug Discovery center.</p> | <p><b>Contact person:</b> Prof. Samir K. Brahmachari, former director of India's main research body - The Council of Scientific and Industrial Research (CSIR); Chief mentor, Open Source Drug Discovery center.</p> | ||
− | <b>Advice:</b> Regarding the law, there is no GM microorganisms that are allowed because of the use of antibiotic markers that makes them unsafe to eat. But for him if we can add a safe vitamin pathway | + | <b>Advice:</b> Regarding the law, there is no GM microorganisms that are allowed because of the use of antibiotic markers that makes them unsafe to eat. But for him if we can add a safe vitamin pathway to a bacterium currently present in food (lactic acid bacteria for example) that will be sterilized but producing enough vitamin to fortify the food, it should be possible. It is not impossible that regulatory issues can undergo changes. Concerning the GMO debate in Europe and India, the main points are different: in India, people don't want GMO to be associated with farmers, they don't want them to be dependent and no one want a monopoly of a particular plant. These issues don't apply to our project for Samir Brahmachari, but labeling would be an problem: the use of our product only depends on people's wish. If people find it beneficial and safe, they would take it. To continue, an accelerated evolution can be more acceptable for a project like ours for the GMO regulation. Also, since our project doesn't imply a big company producing and giving a product, it is more likely to work and be more accepted, as well as the way we want to implement it (give power to people, let them have their own "mini-lab" and produce their bacteria and yeast for their consumption) according to him. |
Prof. Brahmachari visited us this summer and participated to our first workshop. We went to meet him again at the 2nd Annual Open Source Pharma Conference in Frankfurt, Germany at the end of the summer. | Prof. Brahmachari visited us this summer and participated to our first workshop. We went to meet him again at the 2nd Annual Open Source Pharma Conference in Frankfurt, Germany at the end of the summer. |
Revision as of 22:10, 18 November 2015